|
Sign In to gain access to subscriptions and/or personal tools.
|
Nutritional Treatment for Acquired Immunodeficiency Virus-Associated Wasting Using β-Hydroxy β-Methylbutyrate, Glutamine, and Arginine: A Randomized, Double-Blind, Placebo-Controlled Study
Robert H. Clark, MD
Nassau County Medical Center, East Meadow, New York
Getachew Feleke, MD
Nassau County Medical Center, East Meadow, New York
Mehraj Din, MD
Nassau County Medical Center, East Meadow, New York
Tabassum Yasmin, MD
Nassau County Medical Center, East Meadow, New York
Gurpreet Singh, MD
Nassau County Medical Center, East Meadow, New York
Faroque A. Khan, MB, MACP
Nassau County Medical Center, East Meadow, New York
John A. Rathmacher, PhD
Iowa State University, Ames, Iowa, jarat{at}iastate.edu
Background: The current study was designed to examine whether a combination of three nutrients, consisting of β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine, L-glutamine (Gln) and L-arginine (Arg), each of which has been previously shown to slow muscle proteolysis, could synergistically alter the course of muscle wasting in patients with established acquired immunodeficiency syndrome (AIDS). Methods: Sixty-eight human immunodeficiency virus (HIV)-infected patients with a documented weight loss of at least 5% in the previous 3 months were recruited from the HIV clinic at Nassau County Medical Center. The subjects were randomly assigned in a double-blind fashion to receive either placebo containing maltodextrin or the nutrient mixture (HMB/Arg/Gln) containing 3 g HMB, 14 g L-glutamine, and 14 g L-arginine given in two divided doses daily for 8 weeks. Body weights (BW) were recorded weekly and lean body mass (LBM) and fat mass (FM) were measured by air displacement plethysmography and by a single computerized tomography (CT) slice through the thigh at 0, 4, and 8 weeks. Results: Forty-three subjects completed the 8-week protocol, (placebo, n = 21; HMB/Arg/Gln, n = 22). At 8 weeks, the subjects consuming the HMB/Arg/Gln mixture gained 3.0 ± 0.5 kg of BW while those supplemented with the placebo gained 0.37 ± 0.84 kg (p = .009). The BW gain in the HMB/Arg/Gln-treated subjects was predominantly LBM (2.55 ± 0.75 kg) compared with the placebo-supplemented subjects who lost lean mass (-0.70 ± 0.69 kg, p = .003). No significant change in FM gain was observed (0.43 ± 0.83 kg for the group receiving HMB/Arg/Gln and 1.07 ± 0.64 kg for the group receiving the placebo, p > .20). Similar percentage changes in muscle mass and fat mass were observed with CT scans. Immune status was also improved as evident by an increase in CD3 and CD8 cells and a decrease in the HIV viral load with HMB/Arg/Gln supplementation. Conclusions: The data indicate that the HMB/Arg/Gln mixture can markedly alter the course of lean tissue loss in patients with AIDS-associated wasting. (Journal of Parenteral and Enteral Nutrition 24:133-139, 2000)
Journal of Parenteral and Enteral Nutrition, Vol. 24, No. 3,
133-139 (2000)
DOI: 10.1177/0148607100024003133
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Baier, D. Johannsen, N. Abumrad, J. A. Rathmacher, S. Nissen, and P. Flakoll
Year-long Changes in Protein Metabolism in Elderly Men and Women Supplemented With a Nutrition Cocktail of {beta}-Hydroxy-{beta}-methylbutyrate (HMB), L-Arginine, and L-Lysine
JPEN J Parenter Enteral Nutr,
January 1, 2009;
33(1):
71 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Eley, S. T. Russell, and M. J. Tisdale
Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-{alpha} and angiotensin II by {beta}-hydroxy-{beta}-methylbutyrate
Am J Physiol Endocrinol Metab,
December 1, 2008;
295(6):
E1417 - E1426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Eley, S. T. Russell, and M. J. Tisdale
Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by {beta}-hydroxy-{beta}-methylbutyrate
Am J Physiol Endocrinol Metab,
December 1, 2008;
295(6):
E1409 - E1416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. H. Castellanos, M. D. Litchford, and W. W. Campbell
Modular Protein Supplements and Their Application to Long-Term Care
Nutr Clin Pract,
October 1, 2006;
21(5):
485 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. McCarty and K. I. Block
Toward a Core Nutraceutical Program for Cancer Management
Integr Cancer Ther,
June 1, 2006;
5(2):
150 - 171.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga
Nutrition Modulation of Cachexia/Proteolysis
Nutr Clin Pract,
April 1, 2006;
21(2):
155 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Thompson and M. P. Fuhrman
Nutrients and Wound Healing: Still Searching for the Magic Bullet
Nutr Clin Pract,
June 1, 2005;
20(3):
331 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Smith, P. Mukerji, and M. J. Tisdale
Attenuation of Proteasome-Induced Proteolysis in Skeletal Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate in Cancer-Induced Muscle Loss
Cancer Res.,
January 1, 2005;
65(1):
277 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Yarasheski, S. R. Smith, and W. G. Powderly
Reducing plasma HIV RNA improves muscle amino acid metabolism
Am J Physiol Endocrinol Metab,
January 1, 2005;
288(1):
E278 - E284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Smith, S. M. Wyke, and M. J. Tisdale
Mechanism of the Attenuation of Proteolysis-Inducing Factor Stimulated Protein Degradation in Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate
Cancer Res.,
December 1, 2004;
64(23):
8731 - 8735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Society for Parenteral and Enteral Nutrit
Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients
JPEN J Parenter Enteral Nutr,
January 1, 2002;
26(1_suppl):
1SA - 138SA.
[PDF]
|
|
|
|
|
|
|
E. Steiger and C. Ireton-Jones
The Evolution of Home Parenteral Nutrition in the United States
Nutr Clin Pract,
August 1, 2001;
16(4):
236 - 239.
[PDF]
|
|
|
|
|
|
|
S. Nissen, R. L. Sharp, L. Panton, M. Vukovich, S. Trappe, and J. C. Fuller Jr.
{beta}-Hydroxy-{beta}-Methylbutyrate (HMB) Supplementation in Humans Is Safe and May Decrease Cardiovascular Risk Factors
J. Nutr.,
August 1, 2000;
130(8):
1937 - 1945.
[Abstract]
[Full Text]
|
|
|
|
|
